Fundamentals of Liver Disease - Non-Alcoholic Fatty Liver Disease (NAFLD) & Non-Alcoholic Steatohepatitis 2.0 - Non-Credit

4 (1 vote)

DESCRIPTION
There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

Key topic areas:
NAFLD: Diagnosis and Identification of Those at Risk of Disease Progression
Pathogenesis of Non-alcoholic Steatohepatitis
Non-Invasive Determination of Advanced Disease in NAFLD
Lifestyle Interventions: Setting Goals and Recommendations
Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
Bariatric Surgery: Is the Cure for NASH in the OR?
Managing NASH Cirrhosis and Assessment for Liver Transplant
Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
Emerging Treatments for Non-Alcoholic Steatohepatitis

Release date: June 15, 2020
Expiration date: June 14, 2023
Time to complete each module: 30 minutes

CREDITS OFFERED

This is a temporary non-credit version of this course, in which no credits are available due to the age of its content (>3 years old). The course content is being reviewed and a version 3.0 is being prepared, which will bring back the opportunity to earn credit for this course.

COMPONENTS
Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:
-9 online, narrated modules 15 to 20 minutes in length
-Pre- and post-test questions for each module

DIRECTIONS
Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete necessary components to claim either CME or CE. MOC is available for learners who complete and earn CME.

COPYRIGHT 
All faculty in this activity have given their permission for publication ©2020 AASLD.

Learning Objective:
• Identify patients with liver disease, specifically NASH/NAFLD
• Apply diagnostic tests appropriately
• Discuss important counseling
• Recognize treatment/referral priorities
• Identify first line therapies for NASH/NAFLD
• Refer to specialist in a timely and appropriate fashion

This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

Hepatologists
Gastroenterologists
Nurses
Nurse Practitioners
Pharmacists
Physician Assistants
Transplant Coordinators
Surgeons
Fellows/Trainees
Primary Care Physicians
Other healthcare providers

DISCLOSURE OF CONFLICTS OF INTEREST
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

Mary E. Rinella, MD, FAASLD
Faculty
Consulting: AbbVie, NuSirt, NGM Biopharmaceuticals, Novartis, Gilead, Intercept, Genfit, Enanta, BMS, Immuron, CymaBay, Merck, Viking, Madrigal, Genesis, Metacrine, Allergan, Thetis, Fractyl, 3vBio, Coherus, Terns, Boehringer Ingelheim and Takeda
Editorial Board: Hepatology, Clinical Liver Disease (guest associate editor), Seminars in Liver Disease (associate editor in 2017)

Arun J. Sanyal, MD, MBBS
Faculty
Consulting: Novartis, Merck, BMS, Boehringer Ingelheim, Nitto Denko, Tobira, Intercept, Genfit, Aredelyx, Akarna, Syntlogic, Fractyl, Pfizer, Jannsen, Exalenz, Novo Nordisk, Nordic Bioscience, Lilly
Grant/research support: Intercept, Gilead, Tobira, Novartis, Astra Zeneca, Merck, BMS
Stock Options: Genfit
President of Sanyal Bio

Leon A. Adams, MBBS, FRACP, PhD
Faculty
Patents regarding Hepascore
Employer has a licensing agreement with Quest Diagnostics regarding its commercialization

Brent Neuschwander-Tetri, MD
Faculty
Consulting: Allergan, Allysta, Arrowhead, ARTham, Axcella, Blade, Boehringer-Ingelheim, Bristol-Myers Squibb, Conatus, Consynance, Cymabay, Durect, Enanta, Ferring, Fortress, Gelesis, Genfit, Gilead, High Tide, Histolndex, Intercept, Lipocine, Llama, Madrigal, Medimmune, Merck, Metacrine, Mundipharma, NGM, pH-Pharma, Prometheus and Siemens
Grants/research support: Allergan, BMS, Cirius, Cymabay, Enanta, Galectin, Genfit, Gilead, Intercept, Madrigal, NGM and Prometheus

Kathleen E. Corey, MD, MPH, MMSc
Faculty
Nothing to disclose

Philippe Mathurin, MD, PhD
Faculty
Financial Interests: MSD, Abbvie, Gilead Sciences, Bristol-Myers Squibb, Verlyx, Intercept, Janssen-Cilag and Bayer Healthcare pharmaceutical companies

Kymberly D. Watt, MD
Faculty
Co-investigator for industry studies supported by Conatus, Intercept Pharmaceuticals and Gilead

Dawn M. Torres, MD
Faculty
Nothing to disclose

Raj Vuppalanchi, MD, FAASLD
Faculty
Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

Sanjeeva Arora, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose 

Lauren A. Beste, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Amanda J. Chaney, DNP, APRN, FNP-BC
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Royalities: Springer Publishing-Author

Guadalupe Garcia-Tsao, MD, FAASLD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Advisory Board: Intercept, Conatus
Scientific Consultant/Advisor to Industry or Commercial Enterprises, including Development of Education Presentations: Conatus, Galectin
Research Grants: Intercept

Leslie Hayes, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Minhhuyen Nguyen, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Vicki Shah, PA
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board

Raj Vuppalanchi, MD, FAASLD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

Susan Zapatka, MSN
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Dominique Clayton
AASLD Staff
Nothing to disclose

Denise Seise
AASLD Staff
Nothing to disclose

Sheryl Morgan
Amedco LLC Staff
Nothing to disclose

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support:
No commercial support was received for this enduring material activity.

Key:

Complete
Failed
Available
Locked
Module 1: NAFLD - Diagnosis and Identification of Those at Risk of Disease Progression
Module 1 Pre-Test
5 Questions  |  1 attempt  |  0/5 points to pass
5 Questions  |  1 attempt  |  0/5 points to pass
You must register to access.
Module 1: NAFLD - Diagnosis and Identification of Those at Risk of Disease Progression
Open to view video.
Open to view video.
You must register to access.
Module 1 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
You must register to access.
Module 2: Pathogenesis of Non-alcoholic Steatohepatitis
Module 2 Pre-Test
4 Questions  |  1 attempt  |  0/4 points to pass
4 Questions  |  1 attempt  |  0/4 points to pass
You must register to access.
Module 2: Pathogenesis of Non-alcoholic Steatohepatitis
Open to view video.
Open to view video.
You must register to access.
Module 2 Post-Test
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
You must register to access.
Module 3: Non-Invasive Determination of Advanced Disease in NAFLD
Module 3 Pre-Test
5 Questions  |  1 attempt  |  0/5 points to pass
5 Questions  |  1 attempt  |  0/5 points to pass
You must register to access.
Module 3: Non-Invasive Determination of Advanced Disease in NAFLD
Open to view video.
Open to view video.
You must register to access.
Module 3 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
You must register to access.
Module 4: Lifestyle Interventions: Setting Goals and Recommendations
Module 4 Pre-Test
5 Questions  |  1 attempt  |  0/5 points to pass
5 Questions  |  1 attempt  |  0/5 points to pass
You must register to access.
Module 4: Lifestyle Interventions: Setting Goals and Recommendations
Open to view video.
Open to view video.
You must register to access.
Module 4 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
You must register to access.
Module 5: Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
Module 5 Pre-Test
5 Questions  |  1 attempt  |  0/5 points to pass
5 Questions  |  1 attempt  |  0/5 points to pass
You must register to access.
Module 5: Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
Open to view video.
Open to view video.
You must register to access.
Module 5 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
You must register to access.
Module 6: Bariatric Surgery: Is the Cure for NASH in the OR?
Module 6 Pre-Test
5 Questions  |  1 attempt  |  0/5 points to pass
5 Questions  |  1 attempt  |  0/5 points to pass
You must register to access.
Module 6: Bariatric Surgery: Is the Cure for NASH in the OR?
Open to view video.
Open to view video.
You must register to access.
Module 6 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
You must register to access.
Module 7: Managing NASH Cirrhosis and Assessment for Liver Transplant
Module 7 Pre-Test
4 Questions  |  1 attempt  |  0/4 points to pass
4 Questions  |  1 attempt  |  0/4 points to pass
You must register to access.
Module 7: Managing NASH Cirrhosis and Assessment for Liver Transplant
Open to view video.
Open to view video.
You must register to access.
Module 7 Post-Test
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
You must register to access.
Module 8: Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
Module 8 Pre-Test
5 Questions  |  1 attempt  |  0/5 points to pass
5 Questions  |  1 attempt  |  0/5 points to pass
You must register to access.
Module 8: Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
Open to view video.
Open to view video.
You must register to access.
Module 8 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
You must register to access.
Module 9: Emerging Treatments for Non-Alcoholic Steatohepatitis
Module 9 Pre-Test
5 Questions  |  1 attempt  |  0/5 points to pass
5 Questions  |  1 attempt  |  0/5 points to pass
You must register to access.
Module 9: Emerging Treatments for Non-Alcoholic Steatohepatitis
Open to view video.
Open to view video.
You must register to access.
Module 9 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
You must register to access.
Acknowledgement of non-credit
This course not available for credit
This course not available for credit Credit claiming for this course expired in June 2023. While work is underway on updating the course content, this non-credit version is available for your review.
You must register to access.